• iPSC Cardiomyocytes Differentiation
    • Drug Discovery & Disease Modeling
    • cTnT & SMA
    iPSC Cardiomyocytes Differentiation

Cardiomyocytes Differentiation

We provide top-quality service for the directed differentiation of iPSCs into cardiomyocytes using our efficient induction protocol and reagents. We deliver ready-to-use, functional cardiomyocytes that are desirable in vitro models for high content toxicity and drug screening, and cell regeneration research. They are a feasible and physiologically relevant alternative to embryonic stem cells, primary cells, and animal models. 

Get iPSCs to genetically modify and further differentiate into immune cells? We offer fully customizable iPSC generation from human or non-human tissue samples, and our genome editing experts can use CRISPR or TARGATT™  to genetically alter the iPSCs to fit your project requirements. If you need to expedite your experimental timeline, ASC also offers off-the-shelf cardiomyocytes. Contact us today to find the best solution for your projects.

Products and Services
Technical Details

iPSC Differentiation to Cardiomyocytes


Timelines: 4-6 weeks

  1. Recovery, Expansion and Validation of iPSCs/ESCs: estimated 3 weeks
  2. Cardiomyocytes Differentiation: estimated 2-4 weeks
  3. Characterization of differentiated cells by immunocytochemical (ICC) staining: 2 biomarkers (cTNT; SMA): estimated 2-4 days
Support Materials